A new monoclonal antibody against Covid arrives.

The Ministry of Health Decree authorizing the distribution of the long-acting Evusheld monoclonal antibody from AstraZeneca was published in the Official Gazette.

As Aifa explains, it is the combination of two monoclonal antibodies, tixagevimab and cilgavimab. "Since the antibodies bind to different parts of the protein, their use in combination may be more effective than their use alone," explains Aifa.

Monoclonal is a type of protein designed to recognize and bind to an antigen. Tixagevimab and cilgavimab were designed to bind to the spike protein of SARS-CoV-2, the virus responsible for Covid-19, at two different sites. By attaching to the spike protein, they are expected to prevent the virus from entering the body's cells and causing infection.

(Unioneonline / D)

© Riproduzione riservata